GENVOYA (Gilead Sciences Pty Ltd)
Product name
GENVOYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
221 working days (255)
Active ingredients
tenofovir alafenamide fumarate; emtricitabine; elvitegravir; cobicistat
Registration type
EOI
Indication
GENVOYA is now also indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 25kg.